Real-World Treatment Patterns and Outcomes in Patients With Myelofibrosis Treated With First-Line Pacritinib or Ruxolitinib (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-564; Location: LEVEL 3, HALL B3; "These real-world data show that first-line pacritinib is used in advanced cytopenic myelofibrosis patients with lower platelet counts, whereas ruxolitinib is used in patients with higher platelet counts. Despite these differences and the poorer prognosis observed among cytopenic patients, pacritinib- and ruxolitinib-treated patients appeared to have similar 6-month survival probabilities, with both treatments achieving clinically meaningful improvement in spleen size and symptom burden. This abstract was accepted at EHA2026."
Clinical • HEOR • Real-world • Real-world evidence • Myelofibrosis • Oncology
|
|
James Rossetti DO 1; Douglas Tremblay MD 2; Abiola Oladapo PhD 3; Michael Marrone PhDMPH 3; Caleb Paydar MS 4; Djibril Liassou MS 4; Sarah Buckley MD 3; Purvi Suthar PharmD 3; Adina Gegprifti BA 4; Michael Vredenburg PhD 3; Bruce Feinberg DO 4; Naveen Pemmaraju MD 5
|